Carmed Pharmaceuticals, a science-driven company specializing in standardized carvacrol-based formulations, is preparing to expand its U.S. distribution with an upcoming launch on Amazon. The planned rollout marks an important step in increasing accessibility to Carmed's formulations, enabling U.S. consumers to discover and purchase its products through a widely used digital marketplace. Built on a foundation of structured research and formulation science, Carmed develops standardized botanical formulations designed to support immune resilience, cellular health, and overall physiological balance.
Carmed's expansion onto Amazon reflects the company's strategy of pairing scientific development with modern distribution platforms that improve product accessibility and consumer reach. The company aims to meet growing demand for quality-controlled botanical formulations by making its products easier to access through familiar purchasing channels. "Our focus is to deliver formulations that are consistent, standardized, and grounded in scientific methodology," said Mustafa Can, Founder of Carmed Pharmaceuticals. "Expanding onto Amazon allows us to reach a broader audience while maintaining the same commitment to research and quality that defines our work."
As part of its Amazon rollout, Carmed Pharmaceuticals plans to introduce several of its core formulations including Vacrol® Kids Spray, S-Mix®, Vacrol® Capsule, Vacrol-M® Capsule, and Omevaq-3®. Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified. According to the company, all formulations are developed using standardized processes designed to ensure consistency, reproducibility, and quality control across production.
Carmed's formulation approach is supported by ongoing collaboration with academic institutions, laboratories, and medical researchers focused on bioactive compounds and formulation science. In January 2026, a study published in the peer-reviewed journal Plants examined Vacrol® and S-Mix® in preclinical laboratory and in ovo models, contributing to the broader scientific investigation of carvacrol-based formulations and multicomponent botanical interactions. The company emphasizes that this research reflects scientific investigation into formulation science and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.
Carmed's U.S. strategy focuses on expanding availability while maintaining alignment with regulatory standards and long-term scientific positioning. "The upcoming Amazon launch represents an important step in increasing awareness and accessibility for Carmed's formulations in the United States," said Ceren Can, Global Brand Director of Carmed Pharmaceuticals. "We are focused on building a strong foundation in the U.S. market through consistent product quality and a research-driven approach." The company expects to announce product availability and listing details on Amazon in the coming weeks.
